Biocon Biologics and Viatris Receive European Commission Approval for Abevmy (biosimilar, bevacizumab)

 Biocon Biologics and Viatris Receive European Commission Approval for Abevmy (biosimilar, bevacizumab)

Biocon Biologics and Viatris Receive European Commission Approval for Abevmy (biosimilar, bevacizumab)

Shots:

  • The EC has approved the Abevmy (100 & 400mg) for the treatment in metastatic colorectal carcinoma, metastatic breast cancer, NSCLC, glioblastoma, ovarian, cervical, and renal cancer as part of a specific regimen
  • The approval follows CHMP’s positive opinion and is valid in all EU Member States as well as in the EEA countries Iceland, Liechtenstein, and Norway
  • The approval will strengthen Biocon’s portfolio of biosimilars for cancer in the EU, which include biosimilar Trastuzumab and biosimilar Pegfilgrastim

Click here to­ read full press release/ article | Ref: Biocon | Image: Medicircle

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post